ASH 2022 | Evaluating luspatercept in combination with ESAs for the treatment of anemia in LR-MDS
Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the results of a study evaluating the activity of luspatercept in combination with erythropoiesis-stimulating agents (ESAs) to treat anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS). Results demonstrated an almost 36% response rate to the combination after failure with monotherapy, providing clinical evidence for the synergistic activity between luspatercept and ESAs. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Jazz: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; PharmaEssentia: Honoraria, Other, Speakers Bureau; CTI biopharma: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Servio: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; BMS: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Geron: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Taiho: Honoraria, Membership on an entity’s Board of Directors or advisory committees.
